Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-FR Version v15-EN
Language French English
Date Updated 2019-10-17 2019-10-17
Drug Identification Number 02439654 02439654
Brand name ACT BUPROPION XL ACT BUPROPION XL
Common or Proper name BUPROPION XL BUPROPION XL
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients BUPROPION HYDROCHLORIDE BUPROPION HYDROCHLORIDE
Strength(s) 150MG 150MG
Dosage form(s) TABLET (EXTENDED-RELEASE) TABLET (EXTENDED-RELEASE)
Route of administration ORAL ORAL
Packaging size 90 90
ATC code N06AX N06AX
ATC description ANTIDEPRESSANTS ANTIDEPRESSANTS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date
Actual start date 2018-12-01 2018-12-01
Estimated end date 2019-10-31 2019-10-31
Actual end date 2019-10-16 2019-10-16
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Allocating inventory to support regular demand. Cannot support increased demand for this molecule, as well as now delays in releases from the mfg site. Allocating inventory to support regular demand. Cannot support increased demand for this molecule, as well as now delays in releases from the mfg site.
Health Canada comments